Dr. Christopher W. Ryan
Claim this profileOregon Health and Science University
Studies Cancer
Studies Kidney Cancer
23 reported clinical trials
70 drugs studied
About Christopher W. Ryan
Education:
- Earned an MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Completed Residency in Internal Medicine at the University of Chicago in 1997.
- Completed Fellowship in Hematology/Oncology at the University of Chicago in 2000.
- Certified by the American Board of Internal Medicine (Medical Oncology) since 2000.
- Member of the American Society of Clinical Oncology.
- Specializes in the treatment of sarcomas and genitourinary cancers.
- Actively involved in providing patients with the latest treatments through clinical trials.
Area of expertise
1Cancer
Stage IV
PD-L1 positive
Stage III
2Kidney Cancer
Stage IV
PD-L1 positive
Stage III
Affiliated Hospitals
Clinical Trials Christopher W. Ryan is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 210 criteria
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Christopher W. Ryan
Clinical Trial Related3 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Christopher W. Ryan has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Doxorubicin
- Placebo
- Paclitaxel
Breakdown of trials Christopher W. Ryan has run
Cancer
Kidney Cancer
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher W. Ryan specialize in?
Christopher W. Ryan focuses on Cancer and Kidney Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Christopher W. Ryan currently recruiting for clinical trials?
Yes, Christopher W. Ryan is currently recruiting for 7 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Christopher W. Ryan has studied deeply?
Yes, Christopher W. Ryan has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Christopher W. Ryan?
Apply for one of the trials that Christopher W. Ryan is conducting.
What is the office address of Christopher W. Ryan?
The office of Christopher W. Ryan is located at: Oregon Health and Science University, Portland, Oregon 97239 United States. This is the address for their practice at the Oregon Health and Science University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.